Vericel Corporation (VCEL) stock soared 8.47% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The biotechnology company significantly outperformed market expectations, demonstrating robust growth and improved profitability.

The Q3 earnings report revealed several positive highlights: - Revenue reached $67.503 million, surpassing the IBES estimate of $64.6 million. - Earnings per share (EPS) came in at $0.10, beating the estimated loss of $0.01 per share. - Gross profit stood at $49.585 million, with a strong gross margin of 73.5%. - Adjusted EBITDA was $16.996 million, representing a 25% adjusted EBITDA margin. - Net income for the quarter was $5.074 million.

Adding to the optimistic sentiment, Vericel provided a favorable full-year revenue outlook of $272-276 million, which aligns well with the current IBES estimate of $275.3 million for FY2025. This strong performance and positive guidance suggest that Vericel is executing well on its growth strategy and maintaining a solid position in its market segments, driving investor confidence and the significant pre-market stock price increase.